Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 409

1.

Pharmacodynamic Effects, Pharmacokinetics, and Metabolism of the Synthetic Cannabinoid AM-2201 in Male Rats.

Carlier J, Wohlfarth A, Salmeron BD, Scheidweiler KB, Huestis MA, Baumann MH.

J Pharmacol Exp Ther. 2018 Dec;367(3):543-550. doi: 10.1124/jpet.118.250530. Epub 2018 Sep 28.

2.

Prenatal tobacco and marijuana co-use: Impact on newborn neurobehavior.

Stroud LR, Papandonatos GD, McCallum M, Kehoe T, Salisbury AL, Huestis MA.

Neurotoxicol Teratol. 2018 Nov - Dec;70:28-39. doi: 10.1016/j.ntt.2018.09.003. Epub 2018 Sep 26.

PMID:
30266574
3.

Developmental effects of maternal smoking during pregnancy on the human frontal cortex transcriptome.

Semick SA, Collado-Torres L, Markunas CA, Shin JH, Deep-Soboslay A, Tao R, Huestis MA, Bierut LJ, Maher BS, Johnson EO, Hyde TM, Weinberger DR, Hancock DB, Kleinman JE, Jaffe AE.

Mol Psychiatry. 2018 Aug 21. doi: 10.1038/s41380-018-0223-1. [Epub ahead of print]

PMID:
30131587
4.

Decreased Cannabinoid CB1 Receptors in Male Tobacco Smokers Examined With Positron Emission Tomography.

Hirvonen J, Zanotti-Fregonara P, Gorelick DA, Lyoo CH, Rallis-Frutos D, Morse C, Zoghbi SS, Pike VW, Volkow ND, Huestis MA, Innis RB.

Biol Psychiatry. 2018 Nov 15;84(10):715-721. doi: 10.1016/j.biopsych.2018.07.009. Epub 2018 Jul 21.

PMID:
30121138
5.

Co-use of tobacco and marijuana during pregnancy: Pathways to externalizing behavior problems in early childhood.

Godleski SA, Shisler S, Eiden RD, Huestis MA.

Neurotoxicol Teratol. 2018 Sep - Oct;69:39-48. doi: 10.1016/j.ntt.2018.07.003. Epub 2018 Aug 4.

PMID:
30081085
6.

Additive drug-specific and sex-specific risks associated with co-use of marijuana and tobacco during pregnancy: Evidence from 3 recent developmental cohorts (2003-2015).

Massey SH, Mroczek DK, Reiss D, Miller ES, Jakubowski JA, Graham EK, Shisler SM, McCallum M, Huestis MA, Ganiban JM, Shaw DS, Leve LD, Eiden RD, Stroud LR, Neiderhiser JM.

Neurotoxicol Teratol. 2018 Jul - Aug;68:97-106. doi: 10.1016/j.ntt.2018.06.002. Epub 2018 Jun 7.

PMID:
29886244
7.

Recent Self-Reported Cannabis Use Is Associated With the Biometrics of Delta-9-Tetrahydrocannabinol.

Smith MJ, Alden EC, Herrold AA, Roberts A, Stern D, Jones J, Barnes A, O'Connor KP, Huestis MA, Breiter HC.

J Stud Alcohol Drugs. 2018 May;79(3):441-446.

PMID:
29885152
8.

Synthetic cannabinoid BB-22 (QUCHIC): Human hepatocytes metabolism with liquid chromatography-high resolution mass spectrometry detection.

Carlier J, Diao X, Huestis MA.

J Pharm Biomed Anal. 2018 Aug 5;157:27-35. doi: 10.1016/j.jpba.2018.05.007. Epub 2018 May 7.

PMID:
29754040
9.

Prenatal exposure to tobacco and cannabis: Effects on autonomic and emotion regulation.

Eiden RD, Schuetze P, Shisler S, Huestis MA.

Neurotoxicol Teratol. 2018 Jul - Aug;68:47-56. doi: 10.1016/j.ntt.2018.04.007. Epub 2018 May 1.

PMID:
29727701
10.

Drug exposure during pregnancy: analytical methods and toxicological findings.

Concheiro M, Huestis MA.

Bioanalysis. 2018 Apr 1;10(8):587-606. doi: 10.4155/bio-2017-0260. Epub 2018 Mar 21. Review.

PMID:
29561633
11.

In Vitro Metabolite Profiling of ADB-FUBINACA, A New Synthetic Cannabinoid.

Carlier J, Diao X, Wohlfarth A, Scheidweiler K, Huestis MA.

Curr Neuropharmacol. 2017 Jul;15(5):682-691. doi: 10.2174/1570159X15666161108123419.

12.

Cannabinoid Markers in Biological Fluids and Tissues: Revealing Intake.

Huestis MA, Smith ML.

Trends Mol Med. 2018 Feb;24(2):156-172. doi: 10.1016/j.molmed.2017.12.006. Review.

PMID:
29398403
13.

Nabiximols combined with motivational enhancement/cognitive behavioral therapy for the treatment of cannabis dependence: A pilot randomized clinical trial.

Trigo JM, Soliman A, Quilty LC, Fischer B, Rehm J, Selby P, Barnes AJ, Huestis MA, George TP, Streiner DL, Staios G, Le Foll B.

PLoS One. 2018 Jan 31;13(1):e0190768. doi: 10.1371/journal.pone.0190768. eCollection 2018.

14.

Recommendations for Toxicological Investigation of Drug-Impaired Driving and Motor Vehicle Fatalities-2017 Update.

Logan BK, D'Orazio AL, Mohr ALA, Limoges JF, Miles AK, Scarneo CE, Kerrigan S, Liddicoat LJ, Scott KS, Huestis MA.

J Anal Toxicol. 2018 Mar 1;42(2):63-68. doi: 10.1093/jat/bkx082.

PMID:
29186455
15.

Erratum to: Modelling foetal exposure to maternal smoking using hepatoblasts from pluripotent stem cells.

Lucendo-Villarin B, Filis P, Swortwood MJ, Huestis MA, Meseguer-Ripolles J, Cameron K, Iredale JP, O'Shaughnessy PJ, Fowler PA, Hay DC.

Arch Toxicol. 2017 Nov;91(11):3645. doi: 10.1007/s00204-017-2075-x.

PMID:
28980015
16.

Changes in marijuana use symptoms and emotional functioning over 28-days of monitored abstinence in adolescent marijuana users.

Jacobus J, Squeglia LM, Escobar S, McKenna BM, Hernandez MM, Bagot KS, Taylor CT, Huestis MA.

Psychopharmacology (Berl). 2017 Dec;234(23-24):3431-3442. doi: 10.1007/s00213-017-4725-3. Epub 2017 Sep 12.

17.

Acute effects of intravenous cocaine administration on serum concentrations of ghrelin, amylin, glucagon-like peptide-1, insulin, leptin and peptide YY and relationships with cardiorespiratory and subjective responses.

Bouhlal S, Ellefsen KN, Sheskier MB, Singley E, Pirard S, Gorelick DA, Huestis MA, Leggio L.

Drug Alcohol Depend. 2017 Nov 1;180:68-75. doi: 10.1016/j.drugalcdep.2017.07.033. Epub 2017 Aug 31.

18.

Human Hepatocyte Metabolism of Novel Synthetic Cannabinoids MN-18 and Its 5-Fluoro Analog 5F-MN-18.

Diao X, Carlier J, Zhu M, Huestis MA.

Clin Chem. 2017 Nov;63(11):1753-1763. doi: 10.1373/clinchem.2017.277152. Epub 2017 Aug 18.

19.

Optimization of recombinant β-glucuronidase hydrolysis and quantification of eight urinary cannabinoids and metabolites by liquid chromatography tandem mass spectrometry.

Sempio C, Scheidweiler KB, Barnes AJ, Huestis MA.

Drug Test Anal. 2018 Mar;10(3):518-529. doi: 10.1002/dta.2230. Epub 2017 Aug 16.

PMID:
28815938
20.

Erratum to: Modelling foetal exposure to maternal smoking using hepatoblasts from pluripotent stem cells.

Lucendo-Villarin B, Filis P, Swortwood MJ, Huestis MA, Meseguer-Ripolles J, Cameron K, Iredale JP, O'Shaughnessy PJ, Fowler PA, Hay DC.

Arch Toxicol. 2017 Jul 21. doi: 10.1007/s00204-017-2030-x. [Epub ahead of print] No abstract available.

PMID:
28733887
21.

Impact of Novel Psychoactive Substances on Clinical and Forensic Toxicology and Global Public Health.

Huestis MA, Brandt SD, Rana S, Auwärter V, Baumann MH.

Clin Chem. 2017 Oct;63(10):1564-1569. doi: 10.1373/clinchem.2017.274662. Epub 2017 Jun 30. No abstract available.

22.

Modelling foetal exposure to maternal smoking using hepatoblasts from pluripotent stem cells.

Lucendo-Villarin B, Filis P, Swortwood MJ, Huestis MA, Meseguer-Ripolles J, Cameron K, Iredale JP, O'Shaughnessy PJ, Fowler PA, Hay DC.

Arch Toxicol. 2017 Nov;91(11):3633-3643. doi: 10.1007/s00204-017-1983-0. Epub 2017 May 16. Erratum in: Arch Toxicol. 2017 Oct 3;:. Arch Toxicol. 2017 Jul 21;:.

23.

Reports of Adverse Events Associated with Use of Novel Psychoactive Substances, 2013-2016: A Review.

Logan BK, Mohr ALA, Friscia M, Krotulski AJ, Papsun DM, Kacinko SL, Ropero-Miller JD, Huestis MA.

J Anal Toxicol. 2017 Sep 1;41(7):573-610. doi: 10.1093/jat/bkx031. Review.

PMID:
28459969
24.

The acute effect of cannabis on plasma, liver and brain ammonia dynamics, a translational study.

Abulseoud OA, Zuccoli ML, Zhang L, Barnes A, Huestis MA, Lin DT.

Eur Neuropsychopharmacol. 2017 Jul;27(7):679-690. doi: 10.1016/j.euroneuro.2017.03.006. Epub 2017 Apr 26.

25.

Subjective and physiological effects, and expired carbon monoxide concentrations in frequent and occasional cannabis smokers following smoked, vaporized, and oral cannabis administration.

Newmeyer MN, Swortwood MJ, Abulseoud OA, Huestis MA.

Drug Alcohol Depend. 2017 Jun 1;175:67-76. doi: 10.1016/j.drugalcdep.2017.02.003. Epub 2017 Mar 29.

PMID:
28407543
26.

Prenatal Risk and Infant Regulation: Indirect Pathways via Fetal Growth and Maternal Prenatal Stress and Anger.

Schuetze P, Eiden RD, Colder CR, Huestis MA, Leonard KE.

Child Dev. 2018 Mar;89(2):e123-e137. doi: 10.1111/cdev.12801. Epub 2017 Apr 6.

PMID:
28383108
27.

Distinguishing Intake of New Synthetic Cannabinoids ADB-PINACA and 5F-ADB-PINACA with Human Hepatocyte Metabolites and High-Resolution Mass Spectrometry.

Carlier J, Diao X, Scheidweiler KB, Huestis MA.

Clin Chem. 2017 May;63(5):1008-1021. doi: 10.1373/clinchem.2016.267575. Epub 2017 Mar 16.

28.

Oxytocin by intranasal and intravenous routes reaches the cerebrospinal fluid in rhesus macaques: determination using a novel oxytocin assay.

Lee MR, Scheidweiler KB, Diao XX, Akhlaghi F, Cummins A, Huestis MA, Leggio L, Averbeck BB.

Mol Psychiatry. 2018 Jan;23(1):115-122. doi: 10.1038/mp.2017.27. Epub 2017 Mar 14.

29.

In vitro and in vivo human metabolism of a new synthetic cannabinoid NM-2201 (CBL-2201).

Diao X, Carlier J, Zhu M, Pang S, Kronstrand R, Scheidweiler KB, Huestis MA.

Forensic Toxicol. 2017 Jan;35(1):20-32. doi: 10.1007/s11419-016-0326-9. Epub 2016 Jul 6.

30.

Cannabis Edibles: Blood and Oral Fluid Cannabinoid Pharmacokinetics and Evaluation of Oral Fluid Screening Devices for Predicting Δ9-Tetrahydrocannabinol in Blood and Oral Fluid following Cannabis Brownie Administration.

Newmeyer MN, Swortwood MJ, Andersson M, Abulseoud OA, Scheidweiler KB, Huestis MA.

Clin Chem. 2017 Mar;63(3):647-662. doi: 10.1373/clinchem.2016.265371. Epub 2017 Feb 10.

31.

Tobacco Exposure and Conditional Weight-for-Length Gain by 2 Years of Age.

Molnar DS, Rancourt D, Schlauch R, Wen X, Huestis MA, Eiden RD.

J Pediatr Psychol. 2017 Jul 1;42(6):679-688. doi: 10.1093/jpepsy/jsw095.

32.

Evaluation of divided attention psychophysical task performance and effects on pupil sizes following smoked, vaporized and oral cannabis administration.

Newmeyer MN, Swortwood MJ, Taylor ME, Abulseoud OA, Woodward TH, Huestis MA.

J Appl Toxicol. 2017 Aug;37(8):922-932. doi: 10.1002/jat.3440. Epub 2017 Jan 31.

PMID:
28138971
33.

Designer Drugs 2.0.

Huestis MA, Tyndale RF.

Clin Pharmacol Ther. 2017 Feb;101(2):152-157. doi: 10.1002/cpt.575.

PMID:
28084644
34.

Identification of New Synthetic Cannabinoid ADB-CHMINACA (MAB-CHMINACA) Metabolites in Human Hepatocytes.

Carlier J, Diao X, Sempio C, Huestis MA.

AAPS J. 2017 Mar;19(2):568-577. doi: 10.1208/s12248-016-0037-5. Epub 2017 Jan 9.

PMID:
28070717
35.
36.

Naloxone and Metabolites Quantification in Cord Blood of Prenatally Exposed Newborns and Correlations with Maternal Concentrations.

Wiegand SL, Swortwood MJ, Huestis MA, Thorp J, Jones HE, Vora NL.

AJP Rep. 2016 Oct;6(4):e385-e390.

37.

Reprint of "Adolescent cortical thickness pre- and post marijuana and alcohol initiation".

Jacobus J, Castro N, Squeglia LM, Meloy MJ, Brumback T, Huestis MA, Tapert SF.

Neurotoxicol Teratol. 2016 Nov - Dec;58:78-87. doi: 10.1016/j.ntt.2016.11.003. Epub 2016 Nov 15. Review.

PMID:
27856361
38.

Neuropharmacology of 3,4-Methylenedioxypyrovalerone (MDPV), Its Metabolites, and Related Analogs.

Baumann MH, Bukhari MO, Lehner KR, Anizan S, Rice KC, Concheiro M, Huestis MA.

Curr Top Behav Neurosci. 2017;32:93-117. doi: 10.1007/7854_2016_53. Review.

39.

In Vitro Metabolite Profiling of ADB-FUBINACA, A New Synthetic Cannabinoid.

Carlier J, Diao X, Wohlfarth A, Scheidweiler K, Huestis MA.

Curr Neuropharmacol. 2016 Nov 8. [Epub ahead of print]

PMID:
27829332
40.

Metabolism of Carfentanil, an Ultra-Potent Opioid, in Human Liver Microsomes and Human Hepatocytes by High-Resolution Mass Spectrometry.

Feasel MG, Wohlfarth A, Nilles JM, Pang S, Kristovich RL, Huestis MA.

AAPS J. 2016 Nov;18(6):1489-1499. Epub 2016 Aug 5.

PMID:
27495118
41.

Pharmacokinetic Profiles and Pharmacodynamic Effects for Methylone and Its Metabolites in Rats.

Elmore JS, Dillon-Carter O, Partilla JS, Ellefsen KN, Concheiro M, Suzuki M, Rice KC, Huestis MA, Baumann MH.

Neuropsychopharmacology. 2017 Feb;42(3):649-660. doi: 10.1038/npp.2016.213. Epub 2016 Sep 23.

42.

Approaches, Challenges, and Advances in Metabolism of New Synthetic Cannabinoids and Identification of Optimal Urinary Marker Metabolites.

Diao X, Huestis MA.

Clin Pharmacol Ther. 2017 Feb;101(2):239-253. doi: 10.1002/cpt.534. Epub 2016 Nov 24. Review.

PMID:
27727455
43.

Adolescent cortical thickness pre- and post marijuana and alcohol initiation.

Jacobus J, Castro N, Squeglia LM, Meloy MJ, Brumback T, Huestis MA, Tapert SF.

Neurotoxicol Teratol. 2016 Sep - Oct;57:20-29. doi: 10.1016/j.ntt.2016.09.005. Epub 2016 Sep 26. Review.

44.

Cannabinoid disposition in oral fluid after controlled smoked, vaporized, and oral cannabis administration.

Swortwood MJ, Newmeyer MN, Andersson M, Abulseoud OA, Scheidweiler KB, Huestis MA.

Drug Test Anal. 2017 Jun;9(6):905-915. doi: 10.1002/dta.2092. Epub 2016 Oct 13.

45.

A preliminary evaluation of the relationship of cannabinoid blood concentrations with the analgesic response to vaporized cannabis.

Wilsey BL, Deutsch R, Samara E, Marcotte TD, Barnes AJ, Huestis MA, Le D.

J Pain Res. 2016 Aug 31;9:587-98. doi: 10.2147/JPR.S113138. eCollection 2016.

46.

Maternal Buprenorphine Maintenance and Lactation.

Jansson LM, Spencer N, McConnell K, Velez M, Tuten M, Harrow CA, Jones HE, Swortwood MJ, Barnes AJ, Scheidweiler KB, Huestis MA.

J Hum Lact. 2016 Nov;32(4):675-681. doi: 10.1177/0890334416663198. Epub 2016 Sep 26.

PMID:
27563013
47.

Strategies to distinguish new synthetic cannabinoid FUBIMINA (BIM-2201) intake from its isomer THJ-2201: metabolism of FUBIMINA in human hepatocytes.

Diao X, Scheidweiler KB, Wohlfarth A, Zhu M, Pang S, Huestis MA.

Forensic Toxicol. 2016;34:256-267. Epub 2016 Mar 28.

48.

Long-term stability of cannabinoids in oral fluid after controlled cannabis administration.

Scheidweiler KB, Andersson M, Swortwood MJ, Sempio C, Huestis MA.

Drug Test Anal. 2017 Jan;9(1):143-147. doi: 10.1002/dta.2056. Epub 2016 Sep 13.

49.

Tobacco exposure and maternal psychopathology: Impact on toddler problem behavior.

Godleski SA, Eiden RD, Schuetze P, Colder CR, Huestis MA.

Neurotoxicol Teratol. 2016 Sep - Oct;57:87-94. doi: 10.1016/j.ntt.2016.07.003. Epub 2016 Aug 3.

50.

25C-NBOMe and 25I-NBOMe metabolite studies in human hepatocytes, in vivo mouse and human urine with high-resolution mass spectrometry.

Wohlfarth A, Roman M, Andersson M, Kugelberg FC, Diao X, Carlier J, Eriksson C, Wu X, Konradsson P, Josefsson M, Huestis MA, Kronstrand R.

Drug Test Anal. 2017 May;9(5):680-698. doi: 10.1002/dta.2044. Epub 2016 Aug 12.

PMID:
27448631

Supplemental Content

Loading ...
Support Center